Demo
ANEB Nasdaq· Anebulo Pharmaceuticals Inc.
FundamentalsNews digest Peer analysis
Login
ANEB Nasdaq· Anebulo Pharmaceuticals Inc.
Earnings report Q4 2023

ANEBULO PHARMACEUTICALS, INC. Reports Decreased Revenue in Latest Quarter

Segments of Revenue

ANEBULO PHARMACEUTICALS, INC. reported a decrease in revenue for the latest quarter. The company's revenue is divided into two segments: research and development, and general and administrative expenses.

For the three months ended December 31, 2023, research and development revenue amounted to $1.06 million, compared to $1.87 million in the same period last year. Similarly, general and administrative expenses generated $1.70 million in revenue, down from $1.94 million in the previous year's quarter.

Strengths

Despite the decrease in revenue, ANEBULO PHARMACEUTICALS, INC. highlighted several strengths in their financial performance. The company's management commented that the decrease in revenue was primarily due to a decrease in research and development expenses. This suggests that the company has been able to optimize its spending in this area, potentially improving efficiency and cost-effectiveness.

Challenges

The financial performance of ANEBULO PHARMACEUTICALS, INC. in the latest quarter also revealed some challenges. The company reported a loss from operations of $2.76 million, compared to a loss of $3.81 million in the same period last year. This indicates that the company is still facing difficulties in generating profits and achieving positive operating results.

Noteworthy

One noteworthy aspect of ANEBULO PHARMACEUTICALS, INC.'s performance in the latest quarter is the decrease in interest income. The company reported interest income of $75,522, compared to $8,816 in the previous year's quarter. This significant decrease in interest income may have contributed to the overall decrease in revenue for the quarter.

Summary

ANEBULO PHARMACEUTICALS, INC. experienced a decrease in revenue for the latest quarter, primarily driven by a decrease in research and development expenses. Despite this, the company demonstrated strengths in optimizing spending in this area. However, challenges remain as the company reported a loss from operations. The significant decrease in interest income is also noteworthy and may have impacted the overall revenue. Overall, ANEBULO PHARMACEUTICALS, INC. will need to address these challenges and focus on improving profitability in future quarters.

Source documents

Form 10-Q  filed on Feb 13, 2024
12 pages scanned

Reference data

Company financials Q4 revenue 0
Analyst estimates Q4 EPS missed by -5.72%
Sign up to Fey

Get in-depth analysis on thousands of stocks for just $30/month. Cancel anytime.